Cholesterol management gaps before a recurrent coronary event: insights from the Get With The Guidelines - Coronary Artery Disease registry

This study of the Get With The Guidelines-CAD registry reveals that significant gaps in ambulatory cholesterol management persist among patients with known coronary artery disease, with approximately one-third not using statins and over half of users having uncontrolled LDL-C levels, highlighting notable disparities where women and Black and Hispanic patients face higher risks of inadequate treatment prior to recurrent coronary events.

The Gist

Imagine your heart is like a high-performance car engine. For years, you've been driving it, but now it's starting to sputter and smoke. You know the problem: cholesterol is like thick sludge clogging the fuel lines, making it hard for the engine to run smoothly.

Doctors have a very specific recipe to fix this: a daily pill called a statin. Think of statins as a powerful, high-pressure hose that washes away the sludge, keeping the fuel lines clear and the engine running strong. Guidelines say that if you've had a heart problem before, you must use this hose to prevent a second, potentially fatal breakdown.

This paper is like a mechanic's report card on how well we are actually using that hose in the real world. The researchers looked at over 34,000 people who were rushed to the hospital because their "engine" failed again (a heart attack or unstable angina). They wanted to see: Did these patients have their hose turned on before they got sick?

Here is what they found, broken down into simple stories:

1. The "Off" Switch Problem

About one-third of these patients (31.6%) weren't taking their statin pills at all before they ended up in the hospital.

• The Analogy: It's like driving a car with a flat tire for months, ignoring the warning light, and then wondering why you crashed. These patients had a known history of heart disease, yet they weren't using the one tool that could have saved them.

2. The "Weak Water Pressure" Problem

Even among the people who were taking the pills, the results weren't perfect.

• The Analogy: Imagine you have the hose turned on, but the water pressure is too low. The sludge isn't getting washed away fast enough.
• The Data: Among those taking statins, half still had dangerous levels of cholesterol sludge in their blood. Among those not taking statins, three-quarters had dangerous levels.

3. The "Who Gets Left Behind" Disparities

The study found that the "sludge" wasn't distributed equally. Certain groups were more likely to have the hose turned off or the pressure too low.

• Women: They were more likely to be off their medication or have high cholesterol compared to men. It's as if the car manual for women was somehow harder to find or less emphasized.
• Black and Hispanic Patients: Even when they were taking the pills, they were more likely to still have high cholesterol levels compared to White patients.
  • The Metaphor: Imagine two people using the same brand of hose. One person gets a steady, powerful stream that clears the pipes. The other person gets a sputtering trickle that leaves the sludge behind. This study suggests that for Black and Hispanic patients, the "trickle" is more common, even when they are trying to follow the rules.

4. Why Did This Happen?

The researchers looked for clues. They found that:

• Money matters: People without insurance were much more likely to be off their meds. (You can't wash the car if you can't afford the hose).
• Health history matters: Ironically, people with diabetes or heart failure were more likely to be on their meds. It seems that when the engine is screaming "Help!" (like in diabetes), doctors and patients listen more closely. But for others, the warning lights are ignored.
• Location matters: People in the South and Midwest had higher rates of not taking meds than those in the East.

The Big Takeaway

The authors are saying: "We have the cure, but we aren't using it."

Guidelines (the rulebook) have been clear for years: Take the statin, keep the cholesterol low. But in the real world, there is a massive gap between the rulebook and reality.

• The "Clinical Inertia": This is a fancy way of saying that once a patient leaves the doctor's office, the momentum stops. The doctor says "take this," but the patient forgets, can't afford it, or the doctor doesn't check back to see if the "hose" is working.

What Needs to Happen?

The paper suggests we need Quality Improvement Initiatives.

• The Analogy: We need to install an automatic reminder system in the car. Instead of waiting for the engine to smoke, we need a system that checks the oil every week, reminds the driver to fill the tank, and ensures the hose is spraying at full pressure before the crash happens.

In short: We are losing a huge number of preventable heart attacks because we aren't consistently using the simple, effective tools we already have. We need to make sure every patient, regardless of their gender, race, or bank account, gets their "hose" turned on and working at full power.

Technical Summary

1. Problem Statement

Despite established guidelines (2018 AHA/ACC and 2025 ACC/AHA) recommending maximally tolerated statin therapy for patients with known Coronary Artery Disease (CAD) to prevent recurrent events, a significant proportion of patients remain undertreated. Previous data suggested that roughly one-third of US adults with CAD were not on statins, and a majority had Low-Density Lipoprotein Cholesterol (LDL-C) levels above the recommended threshold of 70 mg/dL. However, much of this data predated the 2018 guidelines.

The specific problem addressed is the persistence of ambulatory cholesterol treatment gaps (non-use of statins and uncontrolled LDL-C) in patients who have already suffered a recurrent acute coronary event (Myocardial Infarction or Unstable Angina). The study investigates whether these gaps persist in contemporary practice (2023–2024) and whether significant disparities exist based on sex and race/ethnicity.

2. Methodology

• Study Design: Retrospective cross-sectional analysis.
• Data Source: The Get With The Guidelines (GWTG) – Coronary Artery Disease (CAD) registry, a large national quality improvement initiative in the US.
• Study Population:
  • Inclusion: 34,003 patients aged ≥18 years with known CAD (history of MI, CABG, or PCI) hospitalized for a new STEMI, NSTEMI, or unstable angina between 2023 and 2024.
  • Exclusions: Patients with symptoms first identified in an acute care setting (to focus on ambulatory management gaps), patients on dialysis, and those without data on medication use at admission.
• Key Variables:
  • Primary Outcomes: (1) Non-use of statins prior to admission; (2) LDL-C level ≥70 mg/dL at arrival.
  • Secondary Outcomes: Non-use of statins, ezetimibe, or PCSK9 inhibitors; prescription of high-intensity statins at discharge.
  • Covariates: Socio-demographics (sex, race/ethnicity, insurance, unmet social needs), clinical history (diabetes, heart failure, prior revascularization), and hospital characteristics.
• Statistical Analysis:
  • Generalized Estimating Equation (GEE) Poisson regression with robust variance estimators to account for hospital clustering.
  • Three models were used: Unadjusted (Model 1), partially adjusted for demographics (Model 2), and fully adjusted for all socio-demographic, clinical, and hospital-level variables (Model 3).
  • Prevalence Ratios (PR) were calculated to assess associations.

3. Key Contributions

• Contemporary Evidence: Provides the first large-scale, national assessment of cholesterol management gaps in CAD patients hospitalized for recurrent events using data collected 5 years after the 2018 guidelines.
• Disparity Analysis: Offers granular insights into how sex and race/ethnicity influence both statin non-use and the achievement of LDL-C targets, specifically stratifying by prior statin use.
• Identification of "Clinical Inertia": Highlights that despite guideline recommendations, a substantial number of patients are not receiving therapy or are not achieving targets, suggesting that guidelines alone are insufficient to break clinical inertia in the ambulatory setting.
• Policy Relevance: Identifies specific high-risk subgroups (women, Black and Hispanic patients, and the uninsured) who require targeted quality improvement interventions.

4. Key Results

• Statin Non-Use:
  • 31.6% of patients (10,738/34,003) were not using a statin prior to admission.
  • Sex Disparity: Women were significantly more likely to be non-users than men (Adjusted PR [aPR] 1.08; 95% CI 1.04–1.14).
  • Race/Ethnicity: Non-Hispanic Black patients were less likely to be non-users compared to White patients (aPR 0.91), while Hispanic patients showed no significant difference.
• LDL-C Levels (≥70 mg/dL):
  • Among patients with documented LDL-C (n=23,558), 57.4% had levels ≥70 mg/dL.
  • By Statin Use: 74.6% of statin non-users and 49.8% of statin users had LDL-C ≥70 mg/dL.
  • Sex Disparity: Women were more likely to have LDL-C ≥70 mg/dL than men, regardless of statin use (aPR 1.18 for users; 1.08 for non-users).
  • Race/Ethnicity Disparity: Among statin users, Non-Hispanic Black (aPR 1.30) and Hispanic (aPR 1.11) patients were significantly more likely to have uncontrolled LDL-C compared to White patients. No significant racial differences were found among non-users.
• Other Factors:
  • Insurance: Being uninsured was associated with a 22% higher likelihood of statin non-use (aPR 1.22).
  • Comorbidities: History of diabetes, dyslipidemia, and heart failure was associated with lower rates of statin non-use (likely due to higher perceived need and monitoring).
  • Discharge: Among those discharged alive, 6.4% were not prescribed a statin, and 14.7% were not prescribed high-intensity statins.

5. Significance and Implications

• Missed Opportunities: The study estimates that initiating or intensifying therapy in the ~10,000 patients not on statins could prevent approximately 3,000 recurrent events annually (based on a projected 30% risk reduction).
• Need for Outpatient Focus: While inpatient quality initiatives (like GWTG) have improved post-discharge care, the data reveals a critical failure in ambulatory (outpatient) management leading up to the recurrent event.
• Targeted Interventions:
  • For Women: Strategies are needed to address the dual gap of lower statin use and higher residual LDL-C.
  • For Racial Minorities: While Black patients had slightly better statin adherence, they faced significantly higher rates of uncontrolled LDL-C despite being on therapy, suggesting a need for therapy intensification (e.g., adding ezetimibe or PCSK9 inhibitors) rather than just initiation.
  • For the Uninsured: Economic barriers significantly impact adherence; lowering costs is a critical lever for improvement.
• Conclusion: The persistence of these gaps indicates that current guideline dissemination is insufficient. The authors call for targeted quality improvement initiatives, routine LDL-C monitoring, and timely therapy intensification in the outpatient setting to reduce the burden of recurrent CAD, with a specific focus on eliminating sex and racial/ethnic disparities.